Enanta Pharmaceuticals(ENTA) - 2020 Q3 - Quarterly Report

Form 10-Q Filing Information Registrant Details This section details Enanta Pharmaceuticals, Inc.'s Form 10-Q filing, including incorporation, executive offices, stock listing, and filer status - Enanta Pharmaceuticals, Inc. filed its Q2 2020 Form 10-Q, a Delaware corporation headquartered in Watertown, MA, with common stock listed on NASDAQ under ENTA[1][2] Registrant Status | Status | Value | | :--- | :--- | | Filer Type | Large accelerated filer | | Shell Company | No | | Common Stock Outstanding (July 30, 2020) | 20,072,144 shares | Note Regarding Forward-Looking Statements This section warns that the report contains forward-looking statements, subject to risks and uncertainties that may cause actual results to differ - The report contains forward-looking statements about business, operations, and financial performance, identifiable by terms like 'anticipate,' 'expect,' 'plan,' 'will,' which are subject to known and unknown risks and uncertainties detailed in 'Risk Factors'[8] PART I—FINANCIAL INFORMATION Item 1. Consolidated Financial Statements Presents Enanta Pharmaceuticals' unaudited Q2 2020 consolidated financial statements, including balance sheets, income statements, cash flows, and notes Unaudited Consolidated Balance Sheets Consolidated Balance Sheet Highlights (in thousands) | Metric | June 30, 2020 | September 30, 2019 | | :--- | :--- | :--- | | Total Current Assets | $413,381 | $401,848 | | Total Assets | $511,704 | $489,829 | | Total Current Liabilities | $23,914 | $22,609 | | Total Liabilities | $31,147 | $27,337 | | Total Stockholders' Equity | $480,557 | $462,492 | Unaudited Consolidated Statements of Operations Consolidated Statements of Operations Highlights (in thousands, except per share amounts) | Metric | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Nine Months Ended June 30, 2020 | Nine Months Ended June 30, 2019 | | :--- | :--- | :--- | :--- | :--- | | Royalty Revenue | $18,653 | $44,367 | $98,842 | $153,884 | | Total Operating Expenses | $41,505 | $40,612 | $120,698 | $123,577 | | Income (Loss) from Operations | $(22,852) | $3,755 | $(21,856) | $30,307 | | Net Income (Loss) | $(14,265) | $7,036 | $(6,827) | $37,192 | | Basic Net Income (Loss) Per Share | $(0.71) | $0.36 | $(0.34) | $1.90 | | Diluted Net Income (Loss) Per Share | $(0.71) | $0.33 | $(0.34) | $1.77 | Unaudited Consolidated Statements of Comprehensive Income (Loss) Consolidated Statements of Comprehensive Income (Loss) Highlights (in thousands) | Metric | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Nine Months Ended June 30, 2020 | Nine Months Ended June 30, 2019 | | :--- | :--- | :--- | :--- | :--- | | Net Income (Loss) | $(14,265) | $7,036 | $(6,827) | $37,192 | | Net Unrealized Gains on Marketable Securities, net of tax | $850 | $175 | $1,312 | $561 | | Comprehensive Income (Loss) | $(13,415) | $7,211 | $(5,515) | $37,753 | Unaudited Consolidated Statements of Stockholders' Equity Consolidated Stockholders' Equity Highlights (in thousands) | Metric | June 30, 2020 | September 30, 2019 | | :--- | :--- | :--- | | Common Stock Amount | $201 | $197 | | Additional Paid-In Capital | $321,985 | $298,409 | | Accumulated Other Comprehensive Income | $1,458 | $146 | | Retained Earnings | $156,913 | $163,740 | | Total Stockholders' Equity | $480,557 | $462,492 | Unaudited Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows Highlights (in thousands) | Metric | Nine Months Ended June 30, 2020 | Nine Months Ended June 30, 2019 | | :--- | :--- | :--- | | Net Cash Provided by Operating Activities | $22,549 | $62,873 | | Net Cash Provided by (Used in) Investing Activities | $17,326 | $(34,456) | | Net Cash Provided by Financing Activities | $8,750 | $1,887 | | Net Increase in Cash, Cash Equivalents and Restricted Cash | $48,625 | $30,304 | | Cash, Cash Equivalents and Restricted Cash at End of Period | $100,463 | $94,814 | Unaudited Notes to Consolidated Financial Statements 1. Nature of the Business and Basis of Presentation - Enanta Pharmaceuticals, Inc. is a biotechnology company focused on small molecule drugs for viral infections and liver diseases, with key programs including RSV (EDP-938), HBV (EDP-514), NASH (EDP-305, EDP-297), hMPV, and SARS-CoV-2 (COVID-19), all with Fast Track designation[29] - The company's funding primarily comes from royalties on AbbVie's HCV treatment MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir)[29] - The COVID-19 pandemic led to a decline in AbbVie's HCV sales and Enanta's royalty revenue for Q2 2020, due to reduced patient access to HCV regimens, with the full impact remaining uncertain[30] 2. Summary of Significant Accounting Policies - The company adopted ASU No. 2016-02, Leases (Topic 842), on October 1, 2019, resulting in the recording of $7,151 thousand in ROU assets and $8,622 thousand in lease liabilities, with no material impact on operations or cash flows[34][36] - The company is evaluating the potential impact of ASU No. 2016-13 (Financial Instruments—Credit Losses) effective October 1, 2020, and ASU 2019-12 (Income Taxes) effective October 1, 2021[38] 3. Fair Value of Financial Assets and Liabilities Fair Value of Financial Assets (in thousands) | Asset Type | June 30, 2020 (Total) | September 30, 2019 (Total) | | :--- | :--- | :--- | | Cash Equivalents (Money Market Funds) | $87,608 | $44,569 | | Marketable Securities (U.S. Treasury notes) | $139,902 | $170,515 | | Marketable Securities (Commercial paper) | $57,824 | $66,667 | | Marketable Securities (Corporate bonds) | $137,823 | $111,837 | | Total Financial Assets | $423,157 | $393,588 | - Series 1 nonconvertible preferred stock is measured at fair value as a Level 3 liability, using a probability-weighted valuation model with unobservable inputs like payout probabilities (0%-60%) and a 6.00% discount rate[42] 4. Marketable Securities Available-for-Sale Marketable Securities (in thousands) | Security Type | June 30, 2020 Fair Value | September 30, 2019 Fair Value | | :--- | :--- | :--- | | U.S. Treasury notes | $139,902 | $170,515 | | Corporate bonds | $137,823 | $111,837 | | Commercial Paper | $57,824 | $66,667 | | Total | $335,549 | $349,019 | - Most marketable securities mature within one year, with some corporate bonds and U.S. Treasury notes maturing between one and three years, totaling $65,404 thousand at June 30, 2020[43] 5. Accrued Expenses and Other Long-Term Liabilities Accrued Expenses and Other Liabilities (in thousands) | Category | June 30, 2020 | September 30, 2019 | | :--- | :--- | :--- | | Accrued Research and Development Expenses | $4,775 | $6,936 | | Accrued Payroll and Related Expenses | $3,481 | $3,894 | | Accrued Clinical Manufacturing | $4,004 | $3,447 | | Total Accrued Expenses | $13,576 | $15,920 | | Uncertain Tax Positions | $776 | $1,746 | | Total Other Long-Term Liabilities | $1,058 | $3,100 | 6. AbbVie Collaboration - The company has a collaboration agreement with AbbVie for HCV NS3 and NS3/4A protease inhibitor compounds, including glecaprevir (MAVYRET®/MAVIRET®)[46] - Through June 30, 2020, the company received approximately $1,002 million in payments (license, preferred stock, research funding, milestones, royalties)[46] - Royalties are tiered, ranging from 10% to 20% on AbbVie's net sales allocated to the protease inhibitor[46] 7. Series 1 Nonconvertible Preferred Stock - As of June 30, 2020, 1,931 shares of Series 1 nonconvertible preferred stock were outstanding, carried at fair value as a liability on the consolidated balance sheet[47] 8. Stock-Based Awards - The company grants stock options, performance share units (PSUs), relative total stockholder return units (rTSRUs), and restricted stock units (RSUs) under its 2019 Equity Incentive Plan and older plans[48][50] - As of June 30, 2020, 3,258 thousand stock options were outstanding with a weighted average exercise price of $50.14 and an aggregate intrinsic value of $29,281 thousand[48][50] Stock-Based Compensation Expense (in thousands) | Category | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Nine Months Ended June 30, 2020 | Nine Months Ended June 30, 2019 | | :--- | :--- | :--- | :--- | :--- | | Research and Development | $2,499 | $2,186 | $7,678 | $6,654 | | General and Administrative | $2,256 | $1,978 | $7,152 | $8,060 | | Total Stock-Based Compensation Expense | $4,755 | $4,164 | $14,830 | $14,714 | - As of June 30, 2020, unrecognized stock-based compensation cost totaled $43,977 thousand, expected to be recognized over a weighted average period of 2.5 years[54] 9. Net Income (Loss) Per Share Net Income (Loss) Per Share (in thousands, except per share data) | Metric | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Nine Months Ended June 30, 2020 | Nine Months Ended June 30, 2019 | | :--- | :--- | :--- | :--- | :--- | | Basic Net Income (Loss) Per Share | $(0.71) | $0.36 | $(0.34) | $1.90 | | Diluted Net Income (Loss) Per Share | $(0.71) | $0.33 | $(0.34) | $1.77 | | Weighted Average Common Shares Outstanding (Basic) | 20,020 | 19,673 | 19,897 | 19,549 | | Weighted Average Common Shares Outstanding (Diluted) | 20,020 | 21,105 | 19,897 | 20,999 | - Anti-dilutive common stock equivalents of 3,640 thousand and 3,423 thousand were excluded from diluted net loss per share computations for the three and nine months ended June 30, 2020, respectively, due to net losses[55][57] 10. Income Taxes Income Tax Benefit (in thousands) | Period | Income Tax Benefit | | :--- | :--- | | Three Months Ended June 30, 2020 | $7,142 | | Three Months Ended June 30, 2019 | $866 | | Nine Months Ended June 30, 2020 | $9,558 | | Nine Months Ended June 30, 2019 | $340 | - The income tax benefit for the nine months ended June 30, 2020, was primarily due to a pre-tax loss, federal R&D tax credits, and a federal net operating loss carryback, with the CARES Act allowing NOL carrybacks from fiscal 2018-2020 for up to five years and eliminating the 80% taxable income limitation[58][59] - As of June 30, 2020, the company had $15,289 thousand in net deferred tax assets, including $10,178 thousand from stock compensation and $4,301 thousand in federal R&D tax credit carryforwards, with potential for a valuation allowance due to decreasing royalty revenues and increasing R&D costs[59] 11. Leases - The company has real estate leases for office and laboratory space expiring in September 2022 and August 2024, and an equipment lease[61] - Operating lease cost for the nine months ended June 30, 2020, was $2,631 thousand, with total lease expense of $4,001 thousand including variable costs[61] Future Annual Minimum Lease Payments (in thousands) | Year Ended September 30, | Operating Leases | | :--- | :--- | | 2020 | $1,174 | | 2021 | $4,396 | | 2022 | $2,856 | | 2023 | $608 | | 2024 | $519 | | Total Future Minimum Lease Payments | $9,553 | | Less: Imputed Interest | $(742) | | Total Operating Lease Liabilities | $8,811 | 12. Commitments and Contingencies - The company is not currently a party to any litigation but may face intellectual property infringement claims, providing indemnifications with potentially unlimited maximum future payments without material costs incurred to date[64][65] Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Management discusses financial condition, operations, COVID-19 impact, liquidity, capital resources, and accounting policies for Q2 2020 Overview - Enanta Pharmaceuticals is a biotechnology company developing small molecule drugs for viral infections and liver diseases[69] - The company had $435.4 million in cash and marketable securities at June 30, 2020, expected to fund R&D programs for the foreseeable future[69] - Wholly-owned R&D programs focus on RSV (EDP-938), HBV (EDP-514), and NASH (EDP-305, EDP-297), all with FDA Fast Track designation[69] Our Wholly-Owned Programs - The company's wholly-owned R&D programs are in virology (RSV, HBV, hMPV, SARS-CoV-2) and NASH[71][73] - Key clinical candidates include EDP-938 for RSV (Phase 2b RSVP study ongoing), EDP-514 for HBV (Phase 1a/1b Part 1 completed, Part 2 ongoing, new Phase 1b initiated), and EDP-305 for NASH (Phase 2b ARGON-2 initiated), with EDP-297 (NASH) to initiate Phase 1 in Q3 2020[71][73] - New discovery efforts were launched in January 2020 for hMPV and in March 2020 for SARS-CoV-2 (COVID-19)[71] Our Out-Licensed Products - Through the AbbVie collaboration, the company out-licensed two protease inhibitors, including glecaprevir, which is part of MAVYRET®/MAVIRET® for HCV[74] - All $330.0 million in milestone payments have been earned, with royalties annually tiered, double-digit, per-product on 50% of AbbVie's net sales of MAVYRET/MAVIRET[74] Product Development Pipeline | Product Candidate | Mechanism | Status | | :--- | :--- | :--- | | HCV (glecaprevir-containing combo) | Protease Inhibitor | Marketed by AbbVie | | RSV (EDP-938) | N-Protein Inhibitor | Phase 2b "RSVP" study ongoing | | NASH (EDP-305) | FXR Agonist | Phase 2b "ARGON-2" study ongoing | | HBV (EDP-514) | Core Inhibitor | Two Phase 1b studies in HBV patients ongoing | | NASH (EDP-297) | FXR Agonist Follow-on | Preclinical | | hMPV | Non-Fusion Inhibitor | Discovery | | COVID-19 (SARS-CoV-2 Inhibitor) | SARS-CoV-2 Inhibitor | Discovery | COVID-19 Update - The COVID-19 pandemic has significantly impacted clinical trials, royalty revenues, and business operations[78][80][82] - Enrollment in ARGON-2 and the HBV nuc-suppressed study was paused in March 2020 but resumed in July 2020, with royalty revenues declining for Q2 2020 due to reduced HCV sales and patient volumes[78][80][82] - Despite the impact, the company expects to fund R&D programs with current royalty revenue and $435.4 million in cash and marketable securities as of June 30, 2020, with largely uninterrupted supply chain[80][82] Financial Operations Overview - The company funds wholly-owned R&D programs primarily through AbbVie collaboration payments and existing financial resources[83] - Royalty revenues declined in Q2 2020 due to COVID-19's impact on MAVYRET/MAVIRET sales, with AbbVie reporting $376 million in worldwide net sales for the quarter, down from $780 million in the prior year period[83] - R&D expenses are expected to increase in fiscal 2020, but potential COVID-19 slowdowns could reduce near-term spending, leading to uncertain future profitability due to fluctuating royalty revenues and R&D costs[83] Royalty Revenue - All fiscal 2020 revenue is expected from annually tiered, double-digit royalties on 50% of AbbVie's net sales of MAVYRET/MAVIRET, with no further milestone payments expected[84] Operating Expenses Operating Expenses (in thousands) | Expense Type | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Nine Months Ended June 30, 2020 | Nine Months Ended June 30, 2019 | | :--- | :--- | :--- | :--- | :--- | | Research and Development | $34,682 | $34,461 | $100,070 | $103,494 | | General and Administrative | $6,823 | $6,151 | $20,628 | $20,083 | | Total Operating Expenses | $41,505 | $40,612 | $120,698 | $123,577 | - R&D expenses include personnel, third-party contract costs, laboratory consumables, allocated facility costs, and third-party license fees, expensed as incurred[88] - R&D expenses are expected to increase as wholly-owned programs advance, subject to COVID-19 impacts[88] Results of Operations Comparison of Three Months Ended June 30, 2020 and 2019 Key Financials - Three Months Ended June 30 (in thousands) | Metric | 2020 | 2019 | Change | | :--- | :--- | :--- | :--- | | Royalty Revenue | $18,653 | $44,367 | $(25,714) | | Research and Development | $34,682 | $34,461 | $221 | | General and Administrative | $6,823 | $6,151 | $672 | | Other Income (Expense), Net | $1,445 | $2,415 | $(970) | | Income Tax Benefit | $7,142 | $866 | $6,276 | - Royalty revenue decreased by $25.7 million (57.9%) due to lower MAVYRET/MAVIRET sales, primarily impacted by COVID-19, with AbbVie reporting worldwide net sales of $376 million in Q2 2020 vs. $780 million in Q2 2019[94][97] - R&D expenses were comparable, but virology program expenses increased due to HBV progression and RSVP trial preparations, while liver disease program expenses decreased due to timing of clinical trials[94][97] Comparison of the Nine Months Ended June 30, 2020 and 2019 Key Financials - Nine Months Ended June 30 (in thousands) | Metric | 2020 | 2019 | Change | | :--- | :--- | :--- | :--- | | Revenue | $98,842 | $153,884 | $(55,042) | | Research and Development | $100,070 | $103,494 | $(3,424) | | General and Administrative | $20,628 | $20,083 | $545 | | Other Income (Expense), Net | $5,471 | $6,545 | $(1,074) | | Income Tax Benefit | $9,558 | $340 | $9,218 | - Royalty revenue decreased by $55.0 million (35.8%) due to lower HCV sales from increased competition and COVID-19, while R&D expenses decreased by $3.4 million due to NASH clinical trial timing offset by increased virology program expenses[102][105] Liquidity and Capital Resources - As of June 30, 2020, principal liquidity sources were $435.4 million in cash, cash equivalents, and marketable securities, deemed sufficient for anticipated cash requirements for the foreseeable future despite COVID-19[109][114] Cash Flow Summary - Nine Months Ended June 30 (in thousands) | Cash Flow Activity | 2020 | 2019 | Change | | :--- | :--- | :--- | :--- | | Operating Activities | $22,549 | $62,873 | $(40,324) | | Investing Activities | $17,326 | $(34,456) | $51,782 | | Financing Activities | $8,750 | $1,887 | $6,863 | | Net Increase in Cash, Cash Equivalents and Restricted Cash | $48,625 | $30,304 | $18,321 | - Operating cash flow decreased by $40.3 million due to lower net income, investing cash flow increased by $51.8 million due to marketable securities timing, and financing cash flow increased by $6.9 million from stock option exercises[111][112][113] Off-Balance Sheet Arrangements - The company does not engage in off-balance sheet financing activities and has no interest in variable interest entities[116] Contractual Obligations and Commitments - There were no material changes to total contractual commitments and obligations during the nine months ended June 30, 2020, as previously disclosed in the 2019 Form 10-K[117] Critical Accounting Policies - No material changes to significant accounting policies since September 30, 2019, other than the adoption of ASC 842 (Leases) in Q1 fiscal 2020[118] Recently Issued Accounting Pronouncements - A description of recently issued accounting pronouncements that may potentially impact the company's financial position and results of operations is set forth in Note 2 to the consolidated financial statements[119] Item 3. Quantitative and Qualitative Disclosures about Market Risk This section discusses the company's market risk exposure, mainly interest rate sensitivity on cash and marketable securities - As of June 30, 2020, the company held $435.4 million in cash, cash equivalents, and marketable securities, with a 100 basis point change in market interest rates not expected to materially impact financial condition or operations[120] Item 4. Controls and Procedures This section confirms effective disclosure controls and procedures, with no material changes in internal control over financial reporting - Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of June 30, 2020, with no material changes in internal control over financial reporting identified[122][123] PART II—OTHER INFORMATION Item 1A. Risk Factors This section outlines significant risks impacting business, financial condition, and operations, covering development, commercialization, third-party reliance, IP, industry, and stock volatility Risks Related to Our Business - Financial prospects heavily depend on AbbVie's MAVYRET/MAVIRET sales, which are subject to decline due to COVID-19, competition, pricing pressure, or AbbVie's strategic decisions[126][129] - The company faces intense competition in HCV, NASH, RSV, and HBV markets from larger pharmaceutical and biotechnology companies, risking competitive position if not 'first to market' or lacking compelling advantages[130][132] - The ongoing COVID-19 pandemic adversely affects business, clinical trials, and royalty revenues, causing supply chain disruptions, trial delays, and reduced patient access, with uncertain full impact[134] - The company has limited independent clinical development experience, making successful development and commercialization of wholly-owned product candidates (EDP-938, EDP-514, EDP-305, EDP-297) challenging, and failure to retain key personnel could impair business expansion[135][137][139][142] - Future operating losses are possible due to uncertain AbbVie royalty revenues and increasing R&D expenses, potentially requiring substantial additional financing or forcing delays/termination of product development efforts[143][144] Risks Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates - Clinical drug development is lengthy, expensive, and uncertain, with potential delays from CRO negotiations, regulatory approvals, patient recruitment challenges (exacerbated by COVID-19), and manufacturing issues, harming commercial prospects and increasing costs[147][149] - Product candidates (EDP-938, EDP-514, EDP-305, EDP-297) may have undesirable side effects, potentially delaying or preventing marketing approval, requiring safety warnings, or leading to market withdrawal, with unknown long-term effects of new drug classes[151][153] - Results from earlier clinical trials may not predict later-stage outcomes, and regulatory approval processes are lengthy, unpredictable, and subject to discretion, potentially leading to denial or restrictive labeling[156][157][159] Risks Related to Commercialization of Our Product Candidates - Unfavorable pricing regulations, third-party reimbursement practices, and healthcare reform initiatives (e.g., ACA) could harm the business by reducing demand, limiting coverage, or lowering reimbursement rates for MAVYRET/MAVIRET and future products[163][164][166][167] - The company lacks its own sales and marketing infrastructure, and failure to establish internal capabilities or secure favorable licensing/collaboration agreements could prevent successful market entry for approved product candidates[168] - Commercial success depends on significant market acceptance by physicians, patients, and healthcare payors, influenced by efficacy, safety, clinical indications, pricing, reimbursement, and competitive advantages[170] Risks Related to Our Dependence on Third Parties - Failure to establish new product collaborations could impair development and commercialization, increase cash expenditures, and necessitate additional expertise, while termination of the AbbVie agreement would significantly impact the business[171][173] - Reliance on third-party manufacturers for product candidate supplies carries risks, including regulatory compliance, quality control, supply chain disruptions (e.g., COVID-19), and potential termination of agreements, with significant manufacturing in China exposing geopolitical and epidemic risks[174][176] - Dependence on CROs and other third parties for clinical trials means less control over timing and cost, with failures potentially delaying or terminating trials, compromising data integrity, or leading to disputes[177][178][180] Risks Related to Our Intellectual Property Rights - Inability to obtain or maintain adequate patent protection for product candidates could materially adversely impact the business, as patents may be found invalid or unenforceable if challenged, and government funding grants certain rights[181][182] - Claims of infringement by third parties could lead to costly litigation, substantial damages, or require seeking licenses, potentially diverting management attention and negatively impacting financial condition[185] - Intellectual property rights have limitations, as competitors may develop similar compounds not covered by patents, or changes in patent law could diminish patent value and weaken protection[192][193] - Confidentiality agreements may not prevent unauthorized disclosure of trade secrets, potentially compromising competitive position, and unfavorable IP litigation outcomes could limit R&D or commercialization ability[187][189][191] Risks Related to Our Industry - The company faces inherent product liability risk from clinical testing and commercialization, potentially leading to substantial liabilities, decreased demand, reputational harm, and product recalls, with insurance possibly inadequate[195] - Internal computer systems or those of third parties are vulnerable to security breaches, which could disrupt development programs, lead to data loss, regulatory non-compliance, substantial liability, and reputational damage[196] - Relationships with customers and payors are subject to anti-kickback, fraud and abuse, and other healthcare laws, potentially exposing the company to criminal sanctions, civil penalties, and diminished profits if non-compliance occurs[198][199][201] Risks Related to Our Common Stock - The company's stock price is volatile due to factors like clinical trial results, regulatory actions, AbbVie's sales performance, competition, and general market conditions, with investors relying solely on price appreciation due to no dividend payments[203][204][209][210] - Provisions in corporate charter documents and Delaware law could make an acquisition more difficult, and employment agreements with executive officers include severance benefits upon change of control, potentially harming financial condition[205][207] - Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reports or fraud, harming business and stock price, while analyst coverage impacts stock price and trading volume[208][211] Item 6. Exhibits This section lists Form 10-Q exhibits, including corporate governance, executive certifications, and Inline XBRL financial statements - Exhibits include Restated Certificate of Incorporation, Amended and Restated Bylaws, CEO and CFO certifications, and financial statements in Inline XBRL format[213][214][215][216][217] Signatures This section contains the signature of Paul J. Mellett, Chief Financial Officer, certifying the report filing - The report was signed on August 10, 2020, by Paul J. Mellett, Chief Financial Officer (Principal Financial and Accounting Officer) of Enanta Pharmaceuticals, Inc[223]